Bridgehead International Provides Due Diligence for Investinor AS, Lead Investor in BerGenBio AS

17th February  2012.   Norwegian oncology biopharma company BerGenBio AS has completed an $8.8 million Series A financing round. The financing will be used primarily to take lead compound BGB324 into clinical trials and to develop a companion diagnostic. The lead investors in the raise were Sarsia Seed AS and Investinor AS.

Bridgehead International was appointed by Investinor AS, the Government of Norway venture capital investment corporation, to carry out a due diligence study on BerGenBio AS.  This covered the main technical and commercial elements of the company’s programmes, its business plans and the capacity of the management team to deliver. 

Bridgehead’s CEO, Timothy Fitzgerald, commented: ‘Bridgehead’s expert team was able to provide a rapid, in depth assessment of the BerGenBio portfolio, and to assess this leading edge science in a clear commercial context.   It is very satisfying to see that our advisory work has contributed to this investment round and we wish the company and its investors every success for the future’.

Jon Øyvind Eriksen of Investinor said:  ‘By examining BerGenBio’s main value drivers and evaluating the current status of the company’s programmes, Bridgehead’s consultants provided Investinor with excellent advice which both confirmed our investment thesis. and identified opportunities for Investinor to add value to the company as active owners’.

Notes to editors:

About Bridgehead International Ltd

Bridgehead is a leading strategic healthcare consultancy group, providing a range of services designed to assist clients in achieving extraordinary growth across the product and technology value chain.

Bridgehead's mission is to work with commercial organisations, government agencies and the investment community to ensure that:

• Companies have the funding, structure and strategic focus to deliver high levels of innovation and financial return
• Patients have rapid and broad access to new innovative medicines, medical devices and diagnostic tools, particularly in areas of high unmet need.

With over 50 consultants and 60 associates in Europe, North America and Asia, Bridgehead provides a powerful combination of strategic, scientific, medical, technical, commercial, economic, decision support, modelling and intellectual property skills and experience. 

Bridgehead is globally recognised for its expertise in:

• Market access strategy
• Pricing and reimbursement strategy
• Health economics and health technology assessment
• Opportunity evaluation
• Transaction support.

In 2007 and 2011, Bridgehead was honoured with The Queen’s Award for Enterprise, for outstanding achievement in international trade. The Queen’s Award for Enterprise is the highest honour that can be bestowed upon a UK company and is the UK’s top award for business performance.

In 2009, Bridgehead was voted UK Strategic Advisor of the Year – Healthcare, in the ACQ Finance Magazine’s Global Awards.

For more information about Bridgehead International, please see http://www.bridgehead.com

Contacts at Bridgehead International:

Feb 17, 2012